OPA1 is a ubiquitously expressed, nuclear dynamin-related GTPase, targeted to the inner mitochondrial membrane, which plays a role in mitochondrial fusion.
INTRODUCTION
Autosomal dominant optic atrophy (ADOA; 1) is the most common form of primary inherited optic neuropathy, affecting approximately 1; 12,000 to 1:50,000 individuals and manifesting with insidious onset in early childhood (2, 3) . It is characterised by a mild to moderate progressive loss of visual acuity, colour vision defects, central visual field defects and temporal optic disc pallor (1, 4, 5) . The fundamental pathology of the disease is a loss of retinal ganglion cells (RGCs), particularly those of the papillomacular bundle, followed by ascending atrophy of the optic nerve and loss of optic nerve myelin (4, 6) . Several genetic loci have been implicated in ADOA, including the major locus OPA1 (MIM165500,3q28-q29; 7, 8) , OPA4 (MIM605293, 18q12.2-q12.3; 9), OPA5 (22q12.1-q13.1; 10) and OPA3 (MIM165300, 19q13.2.2-q13.3, which is also associated with cataract; 11, 12) . The OPA1 gene encodes a 960 amino acid mitochondrial dynamin-related guanosine triphosphatase (GTPase; 7, 8) . The protein contains a mitochondrial leader sequence within the highly basic N-terminal targeting the protein to the outer surface of the mitochondrial inner membrane, a GTPase domain, a central dynamin domain that is conserved across all dynamins, and a carboxy terminus of unknown function. Over 117 mutations are reported to date, the majority of which arise in the GTPase and dynamin central regions, coded by exons 8 to 16, and in the C-terminal coding region, exons 27-28. (13-15) . Approximately 50% of these mutations cause premature truncation of the OPA1 protein (16), and thus the functional loss of one allele, causing putative haploinsuffiency of OPA1 (17) .
OPA1, one of a growing family of proteins involved in mitochondrial homeostasis, is associated with regulation of mitochondrial fusion and sequestration 4 of cytochrome c in the mitochondria. It has been demonstrated in a number of cell types that down-regulation of OPA1 with siRNA leads to gross morphological changes in mitochondrial shape, increased fragmentation of the mitochondrial network, dissipation of the mitochondrial membrane potential, disorganisation of the mitochondrial cristae, and release of cytochrome c followed by caspase-dependent apoptotic nuclear events and a block in mitochondrial fusion (18) (19) (20) (21) (22) . Other mitochondrial shaping proteins function with OPA1 to maintain the dynamic control of mitochondrial morphology (23) . These proteins include pro-fusion GTPases: mitofusin (Mfn) 1 and 2; and pro-fission GTPases: dynamin related protein 1 (Drp1) and Fis 1 (18, 24) . OPA1 and Mfn 1 are proposed to have a protective role within the cell (23) , acting as anti-apoptotic GTPases. They protect the cell from spontaneous apoptosis and the detrimental consequences of apoptotic stimuli.
It remains unclear why OPA1 ADOA manifests with an apparently restricted clinical ocular phenotype, comprising RGC loss. OPA1 is ubiquitously expressed throughout the body: in the heart, skeletal muscle, liver, testis, and most abundantly in the brain and retina (7) . In the human retina, OPA1 is present in the cells of the RGC layer, nerve fibre layer, the photoreceptor layer, and the inner and outer plexiform layers (IPL & OPL; (25) . In the mammalian retina, it appears that Opa1 is present in the RGCs, amacrine cells, horizontal cells, IPL and OPL (25) (26) (27) , although Opa1 expression in the mammalian amacrine and horizontal cells and its exact expression profile within the optic nerve remains to be clarified (25, 26) .
In order to address many of the unanswered questions relating to the molecular and cellular pathophysiology of OPA1 ADOA, and to develop systems for testing RGC rescue, we generated a mouse model by screening a mouse DNA ENU- Opa1 isoforms were identified in wild type and mutant mouse retina on 3% agarose gel electrophoresis: the predominant isoform 1 (deletion exon 4b and 5b), isoform 7 (deletion exon 4b) and isoform 8 (full transcript), which correspond to published findings from human and normal mouse retina (Fig. 1E) . RT-PCR with F3 and reverse primers R5 and R5b show that exon 5b is present in retina of both wild type and heterozygous mutants, but exon 4b is only very weakly represented in both ( Figure 1F .) Transcript size is not affected by the Opa1+/-mutation.
To investigate whether the nonsense mutation Q285STOP causes a decrease in Opa1 protein to ca.50% as predicted, we performed Western blot analysis across a wide range of mouse tissues ( Fig. 2A) . The antibody was raised against the Cterminal of Opa1 and recognises native Opa1 in mouse. The results showed that the level of Opa1 protein was significantly reduced in all tissues of Opa1+/-mice (by a mean of approx. 60% Fig. 2B) . A major band of approximately 90 kDa was detected in all protein extracts from retina, brain, heart, liver, skeletal muscle and spleen and from RGC5 cells (which were used as a positive control) from both Opa1+/-and Opa1++ mice ( Fig. 2A) . Secondary bands at ca. 50 and 65 kDa were present in many of the tissues (particularly brain, heart, kidney and spleen), except retina, as in previous studies (7, 8, 26, 29) , possibly representing polyadenylation or protein processing.
Early embryonic lethality in nullizygous Opa1 mice.
Animals heterozygous for Opa1 are viable and fertile. However, Opa1+/-inter-crosses in three lines of mice did not yield any Opa1 -/-live progeny (Table 1.) 8 The complete absence of nullizygous mutants, the wild type to heterozygous progeny ratio of approximately 1:2, and the small mean litter size of Opa1+/-inter-crosses (mean 7.67 versus mean 9.44 for out-crosses) suggested that homozygosity for Opa1 null mutation resulted in embryonic lethality.
To determine the stage of embryonic lethality, timed matings were set up and pregnant females from matings between heterozygous (+/-) mice were sacrificed between 7.5 days post coitum (dpc) and 14.5dpc (Fig. 3) . The embryos were dissected and genotyped. No homozygotes (-/-) were found at 13.5 dpc and decidual vacuity was observed in all litters dissected at 13.5dpc and 14.5dpc. However, homozygotes were observed in litters at 11.dpc, although by this stage they were considerably smaller than littermate controls (Fig. 3F) , displayed growth retardation and demonstrated gross morphological abnormalities (Fig. 3E ). All morphologically normal embryos at all time points dissected were wildtype or heterzygote, however the heterozygote embryos did show a variable phenotype which ranged from normal to growth retardation and forebrain truncation Fig. 3C ). Some of the heterzygotes also showed signs of being absorbed (Fig. 3C ).
One embryo (Fig. 3D ) was of particular interest as it had a severe abnormal phenotype, however difficulties with genotyping prevented us from verifying it's homozygous status. This embryo was smaller than it's littermate control (Fig. 3B) , had 14 somites and displayed an almost completely open neural tube. In a [15] [16] [17] [18] [19] [20] somite embryo the anterior neuropore is completely closed and can be seen almost closed in (Fig. 3A) and (Fig. 3C) . Furthermore, this embryo should have almost completed the process of turning from lordotic to foetal position as observed in (Fig.   3A ) and (Fig. 3C) .
In an 11dpc litter, a homozygote embryo (Fig. 3E ) was identified that had failed to turn embryonically, but also exhibited a severe reduction in the anterior forebrain tissue compared to it's littermate control (Fig. 3F) ; a phenotype regularly observed in heterozygote and homozygote 8.5-11.5dpc embryos.
Mitochondrial fragmentation in Opa1+/-muscle explants.
To assess mitochondrial fusion defects as previously described in opa1 knockdown experiments in vitro (30) we assessed mitochondrial morphology in cells from two 3 month wild type and heterozygous mutant mice. The morphology of the cells grown from muscle explants was classified into two categories. Category I cells displayed a normal network of mitochondria that surrounded the central nucleus.
Category II cells displayed punctuated and completely dispersed mitochondria throughout the cytosol and nucleus, giving a distinct abnormal 'powdered' appearance. Cells from the Opa1+/+ mouse displayed predominantly category I type morphology ( Fig. 4A) and cells from the Opa1+/-mouse displayed mainly category II type morphology (see Fig. 4B ). In three experiments the distinction between wild type and mutant cell morphology was striking under normal culture conditions (see Fig.   4C ).
Morphological changes in optic nerve.
No gross histopathological differences were observed between the organs and tissues of 6 month old Opa1+/-mice compared to Opa1+/+ mice. In particular, brain, cardiac and skeletal muscle all appeared normal on hematoxylin and eosin (H&E) and specific staining (data not shown). Retinal morphology appeared grossly normal in the 6 month old Opa1+/-mice Fig. 5A and B. The different cellular layers of the retina stained with a panel of markers for the retinal cell types (Tuj 1, Calbindin, Calretinin, ChAT, Rhodopsin and OPA1) were indistinguishable from that of littermate controls (data not shown). Statistical analysis using T-test showed that at 6 months of age RGC counts on H&E stained retinal sections were not statistically different between the Opa1+/-and littermate controls, p>0.05 (Fig. 5C ).
On electron microscopy no significant abnormalities were observed in optic nerve sections taken from 6 month old Opa1+/-mice ( Fig. 6A and B) . However, by 9 months of age and at 18 months of age, significant abnormalities were observed in the myelin bundles and optic nerve fascicles of the Opa1+/-mice ( Fig. 6C to F). These changes appear as gross whirls of myelin forming large abnormal forms in multiple areas of the optic nerve, alongside a noticeable loss of myelination in other nerve fibre bundles.
Neurological defects and functional vision anomalies.
Since OPA1 is ubiquitously expressed throughout the body (7), the OPA1 mutation may be predicted to have an effect on other tissues besides the retina, in particular neuromuscular tissue. We therefore carried out a basic neurological examination on wild type and Opa1+/-mice before they undertook visual acuity testing using an optokinetic drum test. The primary SHIRPA screen allows observational assessment of 37 different general health and neurological measures. In ADOA, in whom the only abnormality is the colour of the optic disc. However, one of the key clinical characteristics of patients suffering ADOA is a progressive loss of visual acuity and a highly variable, and often very mild, phenotype. For this reason, we sought to examine the visual acuity of the Opa1+/-mutant mice at 6 and 12 months of age. Sighted C57Bl/6JCrl mice, which were capable of tracking the moving acuity square wave gratings of all frequencies (defined as at least one head tracking movement in the same direction and speed as the drum), and non-sighted C3H mice, who failed to track any of these gratings, confirmed the validity and sensitivity of our test (data not shown, (31) . Opa1+/-mice at 6 and 12 months of age demonstrated tracking of all three square wave gratings, indicating that they are not functionally totally blind ( Fig. 8A and B) . No main effect of genotype or grating was observed at 6 months of age, p>0.05. However, by 12 months of age, the Opa1+/-mice tracked all three gratings less often than littermate controls (Fig. 8B) . Analysis of the time spent tracking across the whole 2 minute test period showed that by 12 months there was a significant main effect of genotype F (1, 33) = 14.99, p< 0.0001, but no main effect of grating p>0.05. This demonstrates an across the board reduction in acuity which was significant between Opa1+/+ and Opa1+/-mice.
A second test, to explore visual function, and in particular RGC loss, used standard mouse running wheels in home cages and the presentation of a light source at night. Mice display considerable nocturnal activity. If a mouse has good visual function and detects the onset of a light source during the night, it will halt all activity, including running wheel activity. However, if a mouse has poor visual function due to loss of photosensitive melanopsin-containing RGCs, and is unable to see the light source, it will continue its running wheel activity. In our experiments the 12 month old Opa1+/+ control mice stopped their running wheel activity during the presentation of the light as expected, however, the Opa1+/-continued their running wheel activity, indicating that they had not seen or detected the onset of the light. Haploinsufficiency may also increase tissue susceptibility to physiologically present and biologically relevant apoptotic stimuli, such as daily exposure to blue light and reactive oxygen species (34) .
The mutation we have modelled lies within 5 bp of a reported human protein truncating mutation (c.869G>T, p.R290Q) which causes ADOA (13) . Exon 8 contains at least one other reported nonsense mutation and 6 missense mutations. Together with exon 9, exon 8 is the exon with the highest number of human disease causing mutations reported (16). Over 65% of OPA1 mutations are substitutions and 66% affect the dynamin central GTPase domain, suggesting that this is an important functional domain. Moreover, this domain is the most highly conserved domain of OPA1 (7) . This data leads us to conclude that we have generated a mutant with an appropriately placed mutation, which mirrors human disease mutation in both position and profile, and emphasises the major importance of the GTPase in Opa1 function.
In the homozygous state our mutation is likely to result in complete loss of normal Opa1 function, thus creating a 'knockout'. The early embryonic lethality of homozygous mutant mice that we report indicates that Opa1 is an essential protein in mammalian development. Humans with OPA1 mutations in ADOA are heterozygous, and thus have at least one functional allele. A compound heterozygous patient (27) has been reported with a more severe phenotype than that which is usual for ADOA. OPA1 is ubiquitously expressed within the body. Clinical evidence (38) demonstrates a widespread, sub-clinical phenotype for patients with OPA1 mutations, which is highly supportive of the widely distributed defect in mitochondria.
However, it is true that neurons demonstrate an overt phenotype, and this is a central neurodegeneration is a secondary consequence to, and often arises considerably later than, axonal impairments (44, 45) . However, we have no evidence that the primary defect is in the myelin sheath of the optic nerve. Indeed, our findings of demyelination in the optic nerve in old animals is in line with published findings (4, 6) on human cases of ADOA in whom optic nerve pathology was available.
Demyelination in the optic nerve was observed in these patients. A loss of photosensitive melanopsin RGCs would be predicted to result in the loss of the ability to maintain entrainment of circadian rhythmicity (46, 47) . This effect is demonstrated by the statistically significant loss of normal responses on the circadian running wheel seen in our animals.
Few patients with ADOA present clinically apparent systemic neurological symptoms or signs, with the exception of hearing loss associated with the R455H OPA1 mutation (48, 49) . Hearing in our Opa1+/-mice was normal. Patients with OPA1 ADOA who have been examined by magnetic resonance spectroscopy (P31) have been found to have post exercise muscle changes in levels of ATP usage and generation. (38) . In our SHIRPA neurological assessment we detected reduced locomotor activity, which may reflect early changes in neurological function and is worthy of further investigation.
In summary, we describe the mutant mouse B6;C3-Opa1 Q285STOP , which displays mitochondrial dysfunction, optic nerve anomalies and visual deficits. This novel mouse model will be a valuable tool, providing a means to directly investigate the pathophysiology of ADOA and the functional role of Opa1 in vivo. Future work will focus on mitochondrial dynamics and morphology.
MATERIALS AND METHODS

Genotype analysis.
Genomic DNA was prepared from mouse tail tips, yolk sacs and embryos.
Opa1 allele specific PCR genotyping was carried out in separate reactions to distinguish wild type and mutant alleles using a common forward primer (F1: 5'-CTCTTCATGTATCTGTGGTC-3') and two reverse primers specific for the wild type (R Wt: 5' TTACCCGTGGTAGGTGATCATG-3') and mutant (R Mut: 5'-TTACCCGTGGTAGGTGATCATA-3') Opa1 alleles (Fig. 1C) . The PCR products were 160bp for both alleles and were distinguished on separate agarose gels by were separated by electrophoresis on 2% agarose gels.
Breeding strategy and embryo analysis.
Opa1 and rd1 allele-specific PCR genotyping was used to direct breeding with wild type C57Bl/6JCrl mice and the removal of the rd1 allele of pdeB (carried by the C3H paternal line) was thus ensured within one generation. Opa1+/-"founder" mice were crossed with C57Bl/6JCrl mice (Charles River, UK) to move the mutation to a C57Bl/6JCrl background. This was continued at G2 to (currently) G4. Opa1+/-F1 and F2 mice were inter-crossed to obtain homozygous Opa1-/-mice: equivalent to "knockouts" for further immediate analysis. All Opa1+/-and Opa1+/+ mice tested were homozygous wild type for the rdl allele.
Opa1+/-were inter-crossed to obtain Opa1-/-embryos. Matings were assumed to take place at midnight, and the day of plug detection until the following midnight was designated 0.5 days post coitum (dpc). Embryos were dissected daily from pregnant dams at 6.5dpc through to 14.5dpc. Whole embryos were observed and photographed using a dissecting microscope. Depending on the size of the embryo, tissue for genotyping was taken from either the tail or embryo yolk sac, before treatment with proteinase K and genotyping by PCR. Whole litters were genotyped in order to identify homozygous Opa1-/-mice.
RT-PCR and Western blot analysis.
Total RNA was isolated from 6 month old mouse retina from 3 wild type and 
Muscle fibroblast culture.
Muscle was removed from two 3-month old Opa1+/-mice and two littermate controls, minced into 2mm pieces and cultured in 6-well plates (Triple Red, UK).
The explants were cultured in DMEM (Sigma, UK) supplemented with 10% fetal bovine serum (FBS; BioSera, UK), 4mM L-glutamine (Invitogen, UK), 1%
penicillin/streptomycin (Sigma, UK) and 1% fungizone (Invitrogen, UK) until cells were visible, at which point, the explants were removed. Cells were grown to 80% confluence in 4 well Lab-Tek chamber slides (Nunc, UK), incubated for 30 mins in 100mM Mitotraker Red CMXRos (Invitrogen, UK) at 37°C and then fixed at 4°C in 4% paraformaldehyde (Sigma, UK) for 30 mins. Slides were mounted in nonfluorescing hydromount (National Diagnostics, UK) and cell morphology assessed under a Leica DM6000B upright confocal microscope. Images of cells from three experiments were taken and categorised for morphology.
Histology and electron microscopy.
Eyes were enucleated from 9 month old Opa1+/-(N= 6) and Opa1+/+ (N=8) littermate control mice. The eyes were placed in 10% neutral buffered formaldehyde (NBF) for fixation at 4°C, dehydrated in graded ethanol series and embedded in paraffin wax (RA Lamb, Eastbourne, UK) for serial sectioning at 7μm. Globe position was marked and orthogonal coronal sections were taken at 1 in 20 intervals and H&E stained in order to identify the optic nerve. Ten retinal sections either side of the optic nerve were then mounted and alternately stained with H&E. Images were taken of each section using a Leica DMR microscope and a Leica DC500 camera with Qwin software for manual RGC counts. Brain, heart, skeletal muscle, liver, kidney and spleen, were taken from four 6-month old Opa1+/-and four littermate controls, fixed in 10% NBF, embedded, sectioned and H&E and crestyl violet stained for histology.
For transmission electron microscopy optic nerves from three 6-month old
Opa1+/-and three littermate controls, four 9-month old Opa1+/-and four littermate controls and two 18-month old Opa1+/-"founders" and two 15 month old C57Bl/6JCrl controls were fixed in strong fixative comprising 4% paraformaldehyde and 5% glutaraldehyde in cacodylate buffer. The tissue was then post-fixed in osmium tetroxide, dehydrated in acetone and embedded in epoxy resin. Ultra thin sections were taken transversely through the optic nerve, stained with uranyl acetate and lead citrate and examined with a Philips CM1000 transmission electron microscope (Biomedical EM Unit, Newcastle University).
Clinical evaluation and functional visual testing.
Mice were subjected to a slit lamp and retinal fundus examination. Subjects were 6-7 month old Opa1+/-mice (N=19) and littermate controls (N=19). Mice were scruffed tightly and each pupil was dilated by placing a drop of 1% atropine (Minims) on the cornea. Anterior segments were examined on a Haag Streit slit lamp and the fundi were examined using indirect ophthalmoscopy (Keeler) and a Super 66D stereo fundus Volk indirect lens. Opa1+/-mice (N=19) and littermate controls (N=19) were tested at the age of 6-7 months of age on the Primary SHIRPA neurological examination screen. Mice were assessed on 37 separate screening tests that form part of the SHIRPA primary protocol, described elsewhere (53) . This included tests of muscle tone, power and co-ordination as well as hearing, using a click box (90 bD and 18-20 kHz). Statistical analysis to assess any differences between groups was performed using parametric T-test or non-parametric Mann Whitney U test, where appropriate.
Mice were tested on the optokinetic drum visual screening test to assess for visual loss at 6-7 months of age and then again at 12-13 months of age. For this second period of testing only 16 Opa1+/-mice were assessed, as three of the original cohort had died of natural causes in the interim. Mice were tested on the optokinetic response test with the use of a rotating optokinetic drum. A digital video camera (JVC, GR-D250) linked to a monitor and a DVD recorder (Hitachi) were used to record the mouse movements (protocol described in detail elsewhere (31, 54, 55) .
Briefly, mice were placed on the platform and allowed to settle for 2 mins. The drum was rotated for 1 min and the mice were observed for a head tracking response. After a 30s break, the drum was rotated in the opposite direction for 1min. The mice were presented with a 2°, 4° and 8° grating (corresponding to 0.25, 0.125 and 0.0625 cycles/ degree respectively) on separate occasions all at the same time of day.
Statistical analysis using a mixed ANOVA design compared the performance of each group of animals over the three different gratings. To validate the protocol and technique in our hands we first tested sighted C57Bl/6JCrl mice (N=3) and nonsighted C3H (N=3) mice on the optokinetic drum.
The same mice were tested for circadian activity on a running wheel apparatus. At least 24 hrs before testing began mice were placed in individual cages containing standard mouse running wheels, that were digitally linked to computer software (AIID software, UK). Mice were on a normal controlled 12hr-12hr lightdark cycle. On day one, 3 hrs into the dark cycle the number of wheel revolutions was recorded in 1 min bins for 1 hr, this represented baseline activity. On day 2, 3 hrs into the dark cycle a light (150W halogen bulb) was presented to all cages for 1 hr.
The number of wheel revolutions was recorded in 1 min bins; this represented the test period activity (56) . The baseline and test period activity was compared between genotypes and a non-parametric Mann Whitney U test performed for statistical analysis. Table 1 .
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